Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 23, 2021 16:08 ET | Source: Ocugen

Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual Global Healthcare Conference

MALVERN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
September 17, 2021 16:52 ET | Source: Ocugen

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
September 07, 2021 17:22 ET | Source: Ocugen

Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright Investment Conferences

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
August 20, 2021 16:34 ET | Source: Ocugen

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
August 06, 2021 07:32 ET | Source: Ocugen

Ocugen Provides Business Update and Second Quarter 2021 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Rolling regulatory submission to Health Canada completed and review process initiated; U.S. FDA talks continueMultiple milestones achieved...
July 30, 2021 08:45 ET | Source: Ocugen

Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET to Discuss Second Quarter 2021 Financial Results and Provide Business Update

MALVERN, Pa., July 30, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
July 16, 2021 16:59 ET | Source: Ocugen

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., July 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness...
July 15, 2021 16:30 ET | Source: Ocugen

Ocugen, Inc. annonce le lancement d’une présentation en continu à Santé Canada pour COVAXIN(MC)

MALVERN, Pennsylvanie, 15 juill. 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ : OCGN), une société biopharmaceutique axée sur la découverte, le développement et la commercialisation de thérapies...
July 15, 2021 07:34 ET | Source: Ocugen

Ocugen, Inc. Announces Initiation of Rolling Submission to Health Canada for COVAXIN™

MALVERN, Pa., July 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing and commercializing gene therapies to cure blindness...
July 02, 2021 17:42 ET | Source: Ocugen

Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Phase 3 Results Demonstrating 77.8% Protection against Overall Disease

Efficacy analysis demonstrates COVAXIN™ to be 93.4% protective against severe symptomatic COVID-19Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variantAdverse...